贝利尤单抗治疗狼疮性肾炎的疗效与安全性:一项3期随机试验的东亚人群亚组分析
BLISS-LN的预设东亚亚组分析纳入142例活检证实的活动性狼疮性肾炎成人患者,按1:1随机接受贝利尤单抗10mg/kg或安慰剂联合标准治疗。第104周贝利尤单抗组主要疗效肾脏缓解率为53% vs 安慰剂组37%(OR 1.76,95%CI 0.88-3.51),第52周为62% vs 37%(OR 2.74,95%CI 1.33-5.64),肾脏相关事件或死亡风险降低(HR 0.37,95%CI 0.15-0.91),安全性两组相似。
要点
- 东亚狼疮性肾炎患者中,贝利尤单抗组第104周主要疗效肾脏缓解率53% vs 安慰剂组37%(OR 1.76,95%CI 0.88-3.51)。
- 第52周主要疗效肾脏缓解率贝利尤单抗组62% vs 安慰剂组37%(OR 2.74,95%CI 1.33-5.64)。
- 贝利尤单抗较安慰剂降低肾脏相关事件或死亡风险(HR 0.37,95%CI 0.15-0.91),安全性两组相似。
核心结论
- 东亚亚组的安全性和疗效特征与BLISS-LN总体人群一致,支持贝利尤单抗治疗东亚狼疮性肾炎患者的获益。
研究设计与样本
- BLISS-LN的预设亚组分析,为3期、安慰剂对照、随机、104周试验。
- 纳入活检证实的活动性狼疮性肾炎成人患者,按1:1随机接受贝利尤单抗或安慰剂联合标准治疗。
- 东亚亚组共142例,来自中国大陆、香港、韩国和台湾,贝利尤单抗组74例,安慰剂组68例。
主要发现
- 第104周主要疗效肾脏缓解率贝利尤单抗组53% vs 安慰剂组37%(OR 1.76,95%CI 0.88-3.51)。
- 第104周完全肾脏缓解率贝利尤单抗组35% vs 安慰剂组25%(OR 1.73,95%CI 0.80-3.74)。
- 第52周主要疗效肾脏缓解率贝利尤单抗组62% vs 安慰剂组37%(OR 2.74,95%CI 1.33-5.64)。
- 贝利尤单抗较安慰剂降低任何时间肾脏相关事件或死亡风险(HR 0.37,95%CI 0.15-0.91)。
- 安全性在各治疗组间相似。
关键数值与推荐
- 主要疗效肾脏缓解定义:第104周尿蛋白-肌酐比值≤0.7g/g,估算肾小球滤过率较 flare 前值下降不超过20%或≥60mL/min/1.73m2,且无治疗失败。
- 完全肾脏缓解定义:第104周尿蛋白-肌酐比值<0.5g/g,估算肾小球滤过率较 flare 前值下降不超过10%或≥90mL/min/1.73m2,且无治疗失败。
- 贝利尤单抗用法为静脉10mg/kg联合标准治疗;标准治疗为口服糖皮质激素联合环磷酰胺诱导后硫唑嘌呤维持,或吗替麦考酚酯用于诱导和维持。
- 诱导期可由研究者决定给予1-3次静脉甲泼尼龙冲击,每次500-1,000mg。
临床怎么用
- 原文未据此给出推荐。
局限性
- 样本量小。
- 缺乏正式显著性检验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Belimumab improved kidney outcomes in patients with active lupus nephritis (LN) in BLISS-LN, leading to its approval in the United States and the European Union. As data on treatment of East Asian patients with LN are limited, we evaluated the efficacy and safety of belimumab in the BLISS-LN East Asian subgroup. STUDY DESIGN: Prespecified subgroup analysis of BLISS-LN, a phase 3, placebo-controlled, randomized 104-week trial. SETTING & PARTICIPANTS: Adults with biopsy-proven, active LN were randomized (1:1) to belimumab or placebo, plus standard therapy. INTERVENTION: Patients were administered intravenous belimumab 10mg/kg, or placebo, plus standard therapy (oral glucocorticoids and either cyclophosphamide for induction followed by azathioprine for maintenance, or mycophenolate mofetil for both induction and maintenance). At the investigator's discretion, 1-3 intravenous pulses of methylprednisolone, 500-1,000mg each, could be administered during induction. OUTCOMES: The primary end point was primary efficacy renal response (PERR; ie, urinary protein-creatinine ratio≤0.7g/g, estimated glomerular filtration rate no more than 20% below preflare value or≥60mL/min/1.73m2, and no treatment failure) at week 104. Key secondary end points included complete renal response (CRR; urinary protein-creatinine ratio<0.5g/g, estimated glomerular filtration rate no more than 10% below preflare value or≥90mL/min/1.73m2, and no treatment failure) at week 104; PERR at week 52; time to kidney-related event or death; and safety. ANALYTICAL APPROACH: PERR and CRR were analyzed using a logistic regression model, and time to a kidney-related event or death was analyzed using a Cox proportional hazards regression model. RESULTS: 142 patients from mainland China, Hong Kong, South Korea, and Taiwan were included (belimumab, n=74; placebo, n=68). At week 104, more belimumab than placebo patients achieved PERR (53% vs 37%; OR, 1.76 [95% CI, 0.88-3.51]) and CRR (35% vs 25%; OR, 1.73 [95% CI, 0.80-3.74]). At week 52, more belimumab than placebo patients achieved PERR (62% vs 37%; OR, 2.74 [95% CI, 1.33-5.64]). Belimumab reduced the risk of a kidney-related event or death compared with placebo at any time (HR, 0.37 [95% CI, 0.15-0.91]). Safety was similar across treatment groups. LIMITATIONS: Small sample size and lack of formal significance testing. CONCLUSIONS: Safety and efficacy profiles were consistent with BLISS-LN overall population, supporting benefits of belimumab treatment in the East Asian subgroup with LN. FUNDING: This study was funded by GSK (GSK study no. BEL114054). TRIAL REGISTRATION: Registered at ClinicalTrials.gov with study number NCT01639339.
引用
- Yu X, Chen N, Xue J, et al. Efficacy and Safety of Belimumab in Patients With Lupus Nephritis: Subgroup Analyses of a Phase 3 Randomized Trial in the East Asian Population. Am J Kidney Dis. 2022. PMID: 36058429. doi:10.1053/j.ajkd.2022.06.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。